Nitroxoline inhibits bladder cancer progression by reversing EMT process and enhancing anti-tumor immunity

• Xu, Naijin

• Lin, Wenfeng

• Sun, Jingkai

• Sadahira, Takuya

• Xu, Abai

• Watanabe, Masami

• Guo, Kai

• Araki, Motoo

• Li, Gonghui

• Liu, Chunxiao

• Nasu, Yasutomo

• Huang, Peng

抄録

Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage of myeloid-derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a potential drug for bladder cancer.

収録刊行物

• Journal of Cancer

  Journal of Cancer 11 (22), 6633-6641, 2020-09-23

  Ivyspring International Publisher

キーワード

• Nitroxoline
• Bladder cancer
• EMT
• immunotherapy preclinical model

詳細情報

• CRID: 1051693803343678080
• NII論文ID: 120006892918
• ISSN: 18379664
• Web Site: https://ousar.lib.okayama-u.ac.jp/60788
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • CiNii Articles